nach oben

Erschienen in:

01.02.2011 | Review

Oncomodulation by human cytomegalovirus: novel clinical findings open new roads

verfasst von: Martin Michaelis, Peter Baumgarten, Michel Mittelbronn, Pablo Hernáiz Driever, Hans Wilhelm Doerr, Jindrich Cinatl Jr.

Erschienen in: Medical Microbiology and Immunology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

The question whether human cytomegalovirus may affect cancer diseases has been discussed (very controversially) for decades. There are convinced believers and strict opponents of the idea that HCMV might be able to play a role in the course of cancer diseases. In parallel, the number of published reports on the topic is growing. Recently published and presented (Ranganathan P, Clark P, Kuo JS, Salamat S, Kalejta RF. A Survey of Human Cytomegalovirus Genomic Loci Present in Glioblastoma Multiforme Tissue Samples. 35th Annual International Herpes Workshop, Salt Lake City, 2010) data on HCMV detection in glioblastoma tissues and colocalisation of HCMV proteins with cellular proteins known to be relevant for glioblastoma progression motivated us to recapitulate the current state of evidence.

M’Fadyan J, Hobday F (1898) Note on the experimental transmission of warts in the dog. J Comp Pathol Ther 11:341–343

Ciuffo G (1907) Innesto positivo con filtrato di verruca volgare. Giorn Ital Mal Venereol 48:12–17

Ellermann V, Bang O (1908) Experimentelle Leukämie bei Hühnern. Zentralbl Bakteriol Abt I Orig 46:595–609

Rous P (1911) Transmission of a malignant new growth by means of a cell-free filtrate. Am J Med Assoc 56:198

Javier RT, Butel JS (2008) The history of tumor virology. Cancer Res 68:7693–7706CrossRefPubMed

McLaughlin-Drubin ME, Munger K (2008) Viruses associated with human cancer. Biochim Biophys Acta 1782:127–150PubMed

Kelly E, Russell SJ (2007) History of oncolytic viruses: genesis to genetic engineering. Mol Ther 15:651–659CrossRefPubMed

Halary F, Pitard V, Dlubek D, Krzysiek R, de la Salle H, Merville P, Dromer C, Emilie D, Moreau JF, Déchanet-Merville J (2005) Shared reactivity of Vdelta2(neg) gammadelta T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells. J Exp Med 201:1567–1578CrossRefPubMed

Devaud C, Bilhere E, Loizon S, Pitard V, Behr C, Moreau JF, Dechanet-Merville J, Capone M (2009) Antitumor activity of gammadelta T cells reactive against cytomegalovirus-infected cells in a mouse xenograft tumor model. Cancer Res 69:3971–3978CrossRefPubMed

10.

Couzi L, Levaillant Y, Jamai A, Pitard V, Lassalle R, Martin K, Garrigue I, Hawchar O, Siberchicot F, Moore N, Moreau JF, Dechanet-Merville J, Merville P (2010) Cytomegalovirus-induced gammadelta T cells associate with reduced cancer risk after kidney transplantation. J Am Soc Nephrol 21:181–188CrossRefPubMed

11.

Erlach KC, Böhm V, Knabe M, Deegen P, Reddehase MJ, Podlech J (2008) Activation of hepatic natural killer cells and control of liver-adapted lymphoma in the murine model of cytomegalovirus infection. Med Microbiol Immunol 197:167–178CrossRefPubMed

12.

Michaelis M, Doerr HW, Cinatl J Jr (2009) The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia 11:1–9PubMed

13.

Cinatl J Jr, Cinatl J, Radsak K, Rabenau H, Weber B, Novak M, Benda R, Kornhuber B, Doerr HW (1994) Replication of human cytomegalovirus in a rhabdomyosarcoma cell line depends on the state of differentiation of the cells. Arch Virol 138:391–401CrossRefPubMed

14.

Cinatl J Jr, Cinatl J, Vogel JU, Rabenau H, Kornhuber B, Doerr HW (1996) Modulatory effects of human cytomegalovirus infection on malignant properties of cancer cells. Intervirology 39:259–269

15.

Cinatl J Jr, Vogel JU, Cinatl J, Weber B, Rabenau H, Novak M, Kornhuber B, Doerr HW (1996) Long-term productive human cytomegalovirus infection of a human neuroblastoma cell line. Int J Cancer 65:90–96CrossRefPubMed

16.

Cinatl J Jr, Cinatl J, Vogel JU, Kotchetkov R, Driever PH, Kabickova H, Kornhuber B, Schwabe D, Doerr HW (1998) Persistent human cytomegalovirus infection induces drug resistance and alteration of programmed cell death in human neuroblastoma cells. Cancer Res 58:367–372PubMed

17.

Cinatl J Jr, Kotchetkov R, Scholz M, Cinatl J, Vogel JU, Driever PH, Doerr HW (1999) Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53. Am J Pathol 155:285–292PubMed

18.

Cinatl J Jr, Scholz M, Doerr HW (2005) Role of tumor cell immune escape mechanisms in cytomegalovirus-mediated oncomodulation. Med Res Rev 25:167–185CrossRefPubMed

19.

Michaelis M, Doerr HW, Cinatl J Jr (2009) Oncomodulation by human cytomegalovirus: evidence becomes stronger. Med Microbiol Immunol 198:79–81CrossRefPubMed

20.

Ho M (2008) The history of cytomegalovirus and its diseases. Med Microbiol Immunol 197:65–73CrossRefPubMed

21.

Besold K, Plachter B (2008) Recombinant viruses as tools to study human cytomegalovirus immune modulation. Med Microbiol Immunol 197:215–222CrossRefPubMed

22.

Böhm V, Podlech J, Thomas D, Deegen P, Pahl-Seibert MF, Lemmermann NA, Grzimek NK, Oehrlein-Karpi SA, Reddehase MJ, Holtappels R (2008) Epitope-specific in vivo protection against cytomegalovirus disease by CD8 T cells in the murine model of preemptive immunotherapy. Med Microbiol Immunol 197:135–144CrossRefPubMed

23.

Campbell AE, Cavanaugh VJ, Slater JS (2008) The salivary glands as a privileged site of cytomegalovirus immune evasion and persistence. Med Microbiol Immunol 197:205–213CrossRefPubMed

24.

Doom CM, Hill AB (2008) MHC class I immune evasion in MCMV infection. Med Microbiol Immunol 197:191–204CrossRefPubMed

25.

Grey F, Hook L, Nelson J (2008) The functions of herpesvirus-encoded microRNAs. Med Microbiol Immunol 197:261–267CrossRefPubMed

26.

Holtappels R, Böhm V, Podlech J, Reddehase MJ (2008) CD8 T-cell-based immunotherapy of cytomegalovirus infection: “proof of concept” provided by the murine model. Med Microbiol Immunol 197:125–134CrossRefPubMed

27.

Lenac T, Arapović J, Traven L, Krmpotić A, Jonjić S (2008) Murine cytomegalovirus regulation of NKG2D ligands. Med Microbiol Immunol 197:159–166CrossRefPubMed

28.

Martin H, Mandron M, Davrinche C (2008) Interplay between human cytomegalovirus and dendritic cells in T cell activation. Med Microbiol Immunol 197:179–184CrossRefPubMed

29.

Maul GG, Negorev D (2008) Differences between mouse and human cytomegalovirus interactions with their respective hosts at immediate early times of the replication cycle. Med Microbiol Immunol 197:241–249CrossRefPubMed

30.

Powers C, Früh K (2008) Rhesus CMV: an emerging animal model for human CMV. Med Microbiol Immunol 197:109–115CrossRefPubMed

31.

Sacher T, Jordan S, Mohr CA, Vidy A, Weyn AM, Ruszics Z, Koszinowski UH (2008) Conditional gene expression systems to study herpesvirus biology in vivo. Med Microbiol Immunol 197:269–276CrossRefPubMed

32.

Seckert CK, Renzaho A, Reddehase MJ, Grzimek NK (2008) Hematopoietic stem cell transplantation with latently infected donors does not transmit virus to immunocompromised recipients in the murine model of cytomegalovirus infection. Med Microbiol Immunol 197:251–259CrossRefPubMed

33.

Stinski MF, Isomura H (2008) Role of the cytomegalovirus major immediate early enhancer in acute infection and reactivation from latency. Med Microbiol Immunol 197:223–231CrossRefPubMed

34.

von Müller L, Mertens T (2008) Human cytomegalovirus infection and antiviral immunity in septic patients without canonical immunosuppression. Med Microbiol Immunol 197:75–82CrossRef

35.

Waller EC, Day E, Sissons JG, Wills MR (2008) Dynamics of T cell memory in human cytomegalovirus infection. Med Microbiol Immunol 197:83–96CrossRefPubMed

36.

Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, Neff MJ, Gibran NS, Huang ML, Santo Hayes TK, Corey L, Boeckh M (2008) Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 300:413–422CrossRefPubMed

37.

Söderberg-Nauclér C (2008) HCMV microinfections in inflammatory diseases and cancer. J Clin Virol 41:218–223CrossRefPubMed

38.

Cinatl J Jr, Vogel JU, Kotchetkov R, Wilhelm Doerr H (2004) Oncomodulatory signals by regulatory proteins encoded by human cytomegalovirus: a novel role for viral infection in tumor progression. FEMS Microbiol Rev 28:59–77CrossRefPubMed

39.

Paulus C, Nitzsche A, Nevels M (2010) Chromatinisation of herpesvirus genomes. Rev Med Virol 20:34–50CrossRefPubMed

40.

Terhune SS, Moorman NJ, Cristea IM, Savaryn JP, Cuevas-Bennett C, Rout MP, Chait BT, Shenk T (2010) Human cytomegalovirus UL29/28 protein interacts with components of the NuRD complex which promote accumulation of immediate-early RNA. PLoS Pathog 6:e1000965CrossRefPubMed

41.

Komano J, Sugiura M, Takada K (1998) Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt’s lymphoma cell line Akata. J Virol 72:9150–9156PubMed

42.

Kassis J, Maeda A, Teramoto N, Takada K, Wu C, Klein G, Wells A (2002) EBV-expressing AGS gastric carcinoma cell sublines present increased motility and invasiveness. Int J Cancer 99:644–651CrossRefPubMed

43.

Abdulkarim B, Sabri S, Zelenika D, Deutsch E, Frascogna V, Klijanienko J, Vainchenker W, Joab I, Bourhis J (2003) Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies. Oncogene 22:2260–2271CrossRefPubMed

44.

Lau SK, Chen YY, Chen WG, Diamond DJ, Mamelak AN, Zaia JA, Weiss LM (2005) Lack of association of cytomegalovirus with human brain tumors. Mod Pathol 18:838–843CrossRefPubMed

45.

Poltermann S, Schlehofer B, Steindorf K, Schnitzler P, Geletneky K, Schlehofer JR (2006) Lack of association of herpesviruses with brain tumors. J Neurovirol 12:90–99CrossRefPubMed

46.

Sabatier J, Uro-Coste E, Pommepuy I, Labrousse F, Allart S, Trémoulet M, Delisle MB, Brousset P (2005) Detection of human cytomegalovirus genome and gene products in central nervous system tumours. Br J Cancer 92:747–750CrossRefPubMed

47.

Slinger E, Maussang D, Schreiber A, Siderius M, Rahbar A, Fraile-Ramos A, Lira SA, Söderberg-Nauclér C, Smit MJ (2010) HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis. Sci Signal 3:ra58

48.

Lucas KG, Bao L, Bruggeman R, Dunham K, Specht C (2010) The detection of CMV pp65 and IE1 in glioblastoma multiforme. J Neurooncol 2010 Sep 5. [Epub ahead of print]

49.

Strååt K, Liu C, Rahbar A, Zhu Q, Liu L, Wolmer-Solberg N, Lou F, Liu Z, Shen J, Jia J, Kyo S, Björkholm M, Sjöberg J, Söderberg-Nauclér C, Xu D (2009) Activation of telomerase by human cytomegalovirus. J Natl Cancer Inst 101:488–497CrossRefPubMed

50.

Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, Nabors LB, Cobbs CG, Britt WJ (2002) Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 62:3347–3350PubMed

51.

Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, Sampson JH (2008) Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol 10:10–18CrossRefPubMed

52.

Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R (2008) Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol 116:79–86CrossRefPubMed

53.

Cinatl J Jr, Nevels M, Paulus C, Michaelis M (2009) Activation of telomerase in glioma cells by human cytomegalovirus: another piece of the puzzle. J Natl Cancer Inst 101:441–443CrossRefPubMed

54.

Prins RM, Cloughesy TF, Liau LM (2008) Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med 359:539–541CrossRefPubMed

55.

Aarnisalo J, Ilonen J, Vainionpää R, Volanen I, Kaitosaari T, Simell O (2003) Development of antibodies against cytomegalovirus, varicella-zoster virus and herpes simplex virus in Finland during the first 8 years of life: a prospective study. Scand J Infect Dis 35:750–753CrossRefPubMed

56.

Wertheim P, Voute PA (1976) Neuroblastoma, Wilms’ tumor, and cytomegalovirus. J Natl Cancer Inst 57:701–703PubMed

57.

Nigro G, Schiavetti A, Booth JC, Clerico A, Dominici C, Krzysztofiak A, Castello M (1995) Cytomegalovirus-associated stage 4S neuroblastoma relapsed stage 4. Med Pediatr Oncol 24:200–203CrossRefPubMed

58.

Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G, Ponzoni M, Tonini GP, Romani M (2002) Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 9:246–251CrossRefPubMed

59.

Allart S, Martin H, Detraves C, Terrasson J, Caput D, Davrinche C (2002) Human cytomegalovirus induces drug resistance and alteration of programmed cell death by accumulation of deltaN-p73alpha. J Biol Chem 277:29063–29068CrossRefPubMed

60.

Blaheta RA, Beecken WD, Engl T, Jonas D, Oppermann E, Hundemer M, Doerr HW, Scholz M, Cinatl J Jr (2004) Human cytomegalovirus infection of tumor cells downregulates NCAM (CD56): a novel mechanism for virus-induced tumor invasiveness. Neoplasia 6:323–331CrossRefPubMed

Titel: Oncomodulation by human cytomegalovirus: novel clinical findings open new roads
verfasst von: Martin Michaelis
Peter Baumgarten
Michel Mittelbronn
Pablo Hernáiz Driever
Hans Wilhelm Doerr
Jindrich Cinatl Jr.
Publikationsdatum: 01.02.2011
Verlag: Springer-Verlag
Erschienen in: Medical Microbiology and Immunology / Ausgabe 1/2011
Print ISSN: 0300-8584
Elektronische ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-010-0177-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Hidden hazards of HCV transmission

Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients

Effect of inhibitors of arachidonic acid metabolism on prostaglandin E2 production by Candida albicans and Candida dubliniensis biofilms

Comparison of pro-inflammatory cytokine expression and cellular signal transduction in human macrophages infected with different influenza A viruses

The underlying mechanisms for the “isolated positivity for the hepatitis B surface antigen (HBsAg)” serological profile